Ulimorelin

Ulimorelin

File:Ulimorelin structure.png

Chemical structure of Ulimorelin

Ulimorelin is a ghrelin agonist that has been investigated for its potential to treat gastrointestinal motility disorders. It is a synthetic compound that mimics the action of the natural hormone ghrelin, which is known to stimulate growth hormone release and increase appetite.

Mechanism of Action

Ulimorelin acts by binding to the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). This interaction stimulates the release of growth hormone from the pituitary gland and enhances gastrointestinal motility by acting on the enteric nervous system.

Clinical Development

Ulimorelin has been studied in clinical trials for its ability to improve gastric emptying in patients with gastroparesis and other motility disorders. Early studies showed promise, indicating that ulimorelin could enhance gastric motility without significant adverse effects. However, later-stage clinical trials did not demonstrate sufficient efficacy to support its continued development for these indications.

Pharmacokinetics

The pharmacokinetic profile of ulimorelin includes rapid absorption and a relatively short half-life, which necessitates frequent dosing to maintain therapeutic levels. It is primarily metabolized in the liver and excreted via the kidneys.

Potential Applications

While ulimorelin's development for gastroparesis was halted, its mechanism of action suggests potential applications in other conditions characterized by impaired gastrointestinal motility. Further research may explore its use in such contexts.

Related Pages

• Ghrelin
• Gastroparesis
• Growth hormone secretagogue receptor